[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 652
1. Moradzadeh Khiavi M, Taghavi Zenouz A, Mesgarzadeh AH, Sabetmehr O, Mahmoudi SM, Kouhsoltani M: Schwannoma in the midline of hard palate: a case report and review of literature. J Dent Res Dent Clin Dent Prospects; 2014;8(2):114-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Schwannoma in the midline of hard palate: a case report and review of literature.
  • Schwannoma is a benign encapsulated slow-growing tumor that originates from Schwann cells of the peripheral nerve sheath.
  • The tongue is the most common site of intraoral schwannomas, followed by the floor of the mouth, palate, gingiva, vestibular mucosa, lips and mental nerve area.
  • We report a rare case of schwannoma in the midline of hard palate with ulcerated surface in a 21-year-old male with a two-month history of a painless swelling on his palate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25093057.001).
  • [ISSN] 2008-210X
  • [Journal-full-title] Journal of dental research, dental clinics, dental prospects
  • [ISO-abbreviation] J Dent Res Dent Clin Dent Prospects
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC4120904
  • [Keywords] NOTNLM ; Palate / oral cavity / schwannoma
  •  go-up   go-down


2. Lechner C, Taylor RL, Todd C, Macdougall H, Yavor R, Halmagyi GM, Welgampola MS: Causes and characteristics of horizontal positional nystagmus. J Neurol; 2014 May;261(5):1009-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty subjects were diagnosed with disorders other than benign positional vertigo (BPV) [vestibular migraine (VM), Ménière's Disease, vestibular schwannoma, unilateral or bilateral peripheral vestibular loss].
  • Two patients with Ménière's Disease had persistent apogeotropic horizontal nystagmus; the peak SPV at 40 s ranged between 28.6 and 49.5 % of the peak.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2010 Nov;120(11):2339-46 [20938976.001]
  • [Cites] Audiol Neurootol. 2010;15(4):241-6 [19893305.001]
  • [Cites] Neurology. 2004 Feb 10;62(3):469-72 [14872034.001]
  • [Cites] Ann Neurol. 1999 Feb;45(2):216-23 [9989624.001]
  • [Cites] J Clin Neurosci. 2013 Aug;20(8):1170-3 [23665081.001]
  • [Cites] Acta Otolaryngol. 2013 Aug;133(8):796-803 [23565838.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2008 Apr;28(2):73-8 [18669071.001]
  • [Cites] Int J Audiol. 2006 Apr;45(4):224-6 [16684703.001]
  • [Cites] Cephalalgia. 2011 Jun;31(8):906-13 [21508087.001]
  • [Cites] Neurol Sci. 2012 Oct;33(5):1189-91 [22187336.001]
  • [Cites] Neurology. 2001 Sep 25;57(6):1085-8 [11571338.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Jul;133(1):107-12 [16025062.001]
  • [Cites] Neurology. 2001 Feb 27;56(4):436-41 [11222783.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1776-81 [17003735.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Nov;131(5):740-6 [15523458.001]
  • [Cites] Int J Otolaryngol. 2011;2011:835671 [21808648.001]
  • [Cites] Neurology. 2005 Jun 14;64(11):1897-905 [15955941.001]
  • [Cites] Acta Otolaryngol. 1957 Mar;47(3):189-201 [13410571.001]
  • [Cites] Acta Otolaryngol. 2006 Jul;126(7):698-704 [16803707.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2010 Apr;30(2):78-86 [20559477.001]
  • [Cites] Stroke. 2009 Feb;40(2):487-91 [19109545.001]
  • (PMID = 24676938.001).
  • [ISSN] 1432-1459
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


3. Springborg JB, Fugleholm K, Poulsgaard L, Cayé-Thomasen P, Thomsen J, Stangerup SE: Outcome after translabyrinthine surgery for vestibular schwannomas: report on 1244 patients. J Neurol Surg B Skull Base; 2012 Jun;73(3):168-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome after translabyrinthine surgery for vestibular schwannomas: report on 1244 patients.
  • The objective of this article is to study the outcome after translabyrinthine surgery for vestibular schwannomas, with special focus on the facial nerve function.
  • Participants were 1244 patients who underwent translabyrinthine surgery during a period of 33 years from 1976 to 2009.
  • Main outcome measures were tumor removal, intraoperative facial nerve preservation, complications, and postoperative facial nerve function.
  • In 84% patients, the tumor was totally resected and in ~85% the nerve was intact during surgery.
  • In patients with normal facial function, overall ~70% had a good outcome (House-Brackmann grade 1 or 2).
  • The chance of a good outcome was related to tumor size with a higher the chance the smaller the tumor, but not to the degree of tumor removal.
  • The translabyrinthine approach is generally efficient in tumor control and with satisfactory facial nerve outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23730545.001).
  • [ISSN] 2193-6331
  • [Journal-full-title] Journal of neurological surgery. Part B, Skull base
  • [ISO-abbreviation] J Neurol Surg B Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3424010
  • [Keywords] NOTNLM ; facial nerve / outcome / translabyrinthine surgery / vestibular schwannoma
  •  go-up   go-down


Advertisement
4. Canbay S, Hasturk AE, Basmaci M, Erten F, Harman F: Management of Thoracal and Lumbar Schwannomas Using a Unilateral Approach without Instability: An Analysis of 15 Cases. Asian Spine J; 2012 Mar;6(1):43-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Thoracal and Lumbar Schwannomas Using a Unilateral Approach without Instability: An Analysis of 15 Cases.
  • PURPOSE: The objectives of this study were to determine and discuss the surgical planning of patients who underwent operations following diagnoses of thoracal and lumbar spinal schwannomas.
  • We also aimed to discuss the application of unilateral hemilaminectomy for the microsurgery of schwannomas.
  • OVERVIEW OF LITERATURE: Schwannomas are located in different regions and sites.
  • Unilateral laminectomy without stabilization of the spine provides a more minimally invasive removal of the tumor.
  • METHODS: In this retrospective study, 15 patients with spinal schwannomas were evaluated with regards to age, sex, onset history, neurological findings, tumor locations, McCormick scale, surgical procedure, and operational results.
  • Extensions of tumors cause problem for the surgeon in terms of approach, resectability of the tumor, and stability of the spine.
  • The tumor was located in the lumbar region in 9 patients, in the thoracic region in 2 patients, and in the thoracolumbar junction in 4 patients.
  • The paramedian route was used to explore the extraspinal part of the tumor.
  • CONCLUSIONS: Resection of giant schwannomas is challenging and usually requires a different approach.
  • We describe the complete resection of complex dumbbell or paraspinal schwannomas of the thoracic and lumbar spine by unilateral hemilaminectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22439087.001).
  • [ISSN] 1976-7846
  • [Journal-full-title] Asian spine journal
  • [ISO-abbreviation] Asian Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3302914
  • [Keywords] NOTNLM ; Instability / Management / Thoracolumbar Schwannoma / Unilateral approach
  •  go-up   go-down


5. Park KT, Ahn Y, Kim KH, Kwon TK: Schwannoma mimicking laryngocele. Clin Exp Otorhinolaryngol; 2010 Sep;3(3):166-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Schwannoma mimicking laryngocele.
  • A schwannoma of the larynx is a rare benign tumor that usually presents as a submucosal mass in the pyriform sinus and the aryepiglottic space, and this type of schwannoma constitutes a diagnostic and therapeutic challenge for otolaryngologists.
  • We present here two cases of supraglottic schwannomas that were misdiagnosed as laryngoceles.
  • We discuss the clinical and imaging findings and the management of this rare neoplasm with focusing on the differential diagnosis of laryngeal schwannoma and laryngocele.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20978630.001).
  • [ISSN] 2005-0720
  • [Journal-full-title] Clinical and experimental otorhinolaryngology
  • [ISO-abbreviation] Clin Exp Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2958503
  • [Keywords] NOTNLM ; Larynx / Neurogenic tumor / Schwannoma
  •  go-up   go-down


6. Manchanda PK, Jones GN, Lee AA, Pringle DR, Zhang M, Yu L, La Perle KM, Kirschner LS: Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors. Oncogene; 2013 Jul 25;32(30):3491-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors.
  • Schwannomas are peripheral nerve sheath tumors that often occur in the setting of an inherited tumor predisposition syndrome, including neurofibromatosis types 1 (NF1) and 2 (NF2), familial schwannomatosis and Carney complex.
  • Loss of the NF2 tumor suppressor (encoding NF2, or Merlin) is associated with upregulation of the Rac1 small GTPase, which is thought to have a key role in mediating tumor formation.
  • In prior studies, we generated a mouse model of schwannomas by performing tissue-specific knockout (KO) of the Carney complex gene Prkar1a, which encodes the type 1A regulatory subunit of protein kinase A.
  • To assess the requirement for Rac1 in schwannoma formation, we generated a double KO (DKO) of Prkar1a and Rac1 in Schwann cells and monitored tumor formation.
  • Loss of Rac1 reduced tumor formation by reducing proliferation and enhancing apoptosis.
  • Surprisingly, the reduction of tumor formation was accompanied by re-expression of the Nf2 protein.
  • These in vivo data indicate that activation of Rac1 is responsible for suppression of Nf2 protein production; deficiency of Nf2 in Schwann cells leads to loss of cellular growth control and tumor formation.
  • [MeSH-major] Cyclic AMP-Dependent Protein Kinase RIalpha Subunit / physiology. Genes, Neurofibromatosis 2. Neurilemmoma / genetics. Neuropeptides / physiology. rac GTP-Binding Proteins / physiology
  • [MeSH-minor] Animals. Down-Regulation / genetics. Mice. Mice, Knockout. Schwann Cells / pathology. rac1 GTP-Binding Protein


7. Celis-Aguilar E, Lassaletta L, Gavilán J: Cochlear implantation in patients with neurofibromatosis type 2 and patients with vestibular schwannoma in the only hearing ear. Int J Otolaryngol; 2012;2012:157497
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cochlear implantation in patients with neurofibromatosis type 2 and patients with vestibular schwannoma in the only hearing ear.
  • Cochlear implants are a new surgical option in the hearing rehabilitation of patients with neurofibromatosis type 2 (NF2) and patients with vestibular schwannoma (VS) in the only hearing ear.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22518152.001).
  • [ISSN] 1687-921X
  • [Journal-full-title] International journal of otolaryngology
  • [ISO-abbreviation] Int J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3299335
  •  go-up   go-down


8. Petrilli AM, Garcia J, Bott M, Klingeman Plati S, Dinh CT, Bracho OR, Yan D, Zou B, Mittal R, Telischi FF, Liu XZ, Chang LS, Welling DB, Copik AJ, Fernández-Valle C: Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. Oncotarget; 2017 May 09;8(19):31666-31681
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
  • Neurofibromatosis type 2 (NF2) is a genetic syndrome that predisposes individuals to multiple benign tumors of the central and peripheral nervous systems, including vestibular schwannomas.
  • Loss of function of merlin encoded by the NF2 tumor suppressor gene leads to activation of multiple mitogenic signaling cascades, including platelet-derived growth factor receptor (PDGFR) and SRC in Schwann cells.
  • The goal of this study was to determine whether ponatinib, an FDA-approved ABL/SRC inhibitor, reduced proliferation and/or survival of merlin-deficient human Schwann cells (HSC).
  • A similar phosphorylation pattern was observed in phospho-protein arrays of human vestibular schwannoma samples compared to normal HSC.
  • These changes were associated with decreased cyclin D1 and increased p27Kip1levels, leading to a G1 cell-cycle arrest as assessed by Western blotting and flow cytometry.
  • These results suggest that ponatinib is a potential therapeutic agent for NF2-associated schwannomas and warrants further in vivo investigation.


9. Ren Y, Sagers JE, Landegger LD, Bhatia SN, Stankovic KM: Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas. Sci Rep; 2017 Oct 10;7(1):12922
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas.
  • Vestibular schwannoma (VS) is the most common tumor of the cerebellopontine angle, and it typically presents with sensorineural hearing loss.
  • The genomic landscape of schwannoma is complex and many of the molecules implicated in VS pathogenesis represent targets not amenable to antibody-based or small molecule therapeutics.
  • Tumor-targeted delivery of small interfering RNA (siRNA) therapeutics provides a direct and effective means to interrogate targets while minimizing off-target effects.
  • To establish a preclinical model for therapeutic inhibition of putative targets in VS, archived tumor specimens, fresh tumor cells derived from patients with sporadic VS, and an established schwannoma cell line were screened.
  • Nanoparticles directed by the tumor-homing peptide iRGD were selectively taken up by primary VS cultures in vitro via interactions with αvβ3/β5 integrins and neuropilin-1 (NRP-1).
  • Taken together, our results provide a proof of principle for tumor-targeted, nanoparticle-mediated delivery of siRNA to VS and establish a novel platform for the development and pre-clinical screening of molecular therapeutics against vs.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2014 Sep;16(9):1196-209 [24558021.001]
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):1005-15 [16823371.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2085-8 [9851930.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):665-9 [16021573.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):542-6 [9181576.001]
  • [Cites] Nature. 2010 Apr 15;464(7291):1067-70 [20305636.001]
  • [Cites] Hum Gene Ther. 2006 Jan;17(1):20-30 [16409122.001]
  • [Cites] Audiol Neurootol. 2006;11(6):357-65 [16988499.001]
  • [Cites] Cancer Cell Int. 2007 Oct 02;7:16 [17910753.001]
  • [Cites] Science. 2010 May 21;328(5981):1031-5 [20378772.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6649-55 [11559528.001]
  • [Cites] Chem Biol. 2007 Jan;14(1):107-15 [17254956.001]
  • [Cites] J Proteome Res. 2011 Sep 2;10(9):3845-51 [21740021.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):806-13 [15510161.001]
  • [Cites] Environ Sci Technol. 2010 Feb 15;44(4):1260-6 [20099802.001]
  • [Cites] Clin Exp Rheumatol. 2005 Jul-Aug;23(4):469-74 [16095114.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1180-4 [19407801.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62 [19805273.001]
  • [Cites] Neurosurg Focus. 2012 Sep;33(3):E1 [22937843.001]
  • [Cites] J Neurooncol. 2015 Apr;122(2):313-20 [25567352.001]
  • [Cites] Sci Rep. 2015 Dec 22;5:18599 [26690506.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):583-92 [16862189.001]
  • [Cites] Arthritis Rheum. 2006 Jun;54(6):1867-77 [16729293.001]
  • [Cites] J Clin Invest. 2017 May 1;127(5):2007-2018 [28414297.001]
  • [Cites] ACS Nano. 2016 Aug 23;10(8):7926-33 [27429164.001]
  • [Cites] J Vis Exp. 2017 Jun 20;(124):null [28654042.001]
  • [Cites] Cancer Cell. 2009 Dec 8;16(6):510-20 [19962669.001]
  • [Cites] Laryngoscope. 2012 Jan;122(1):174-89 [22109824.001]
  • [Cites] Otol Neurotol. 2013 Jun;34(4):748-54 [23512073.001]
  • [Cites] Mol Oncol. 2015 Aug;9(7):1359-70 [25891780.001]
  • [Cites] Mol Pharm. 2014 Feb 3;11(2):486-95 [24387132.001]
  • [Cites] Cancer Res. 2013 Apr 15;73(8):2412-7 [23423979.001]
  • [Cites] Nat Rev Drug Discov. 2009 Feb;8(2):129-38 [19180106.001]
  • [Cites] Annu Rev Biomed Eng. 1999;1:241-63 [11701489.001]
  • [Cites] Clin Neurosurg. 1990;36:347-52 [2295209.001]
  • [Cites] Angew Chem Int Ed Engl. 2016 Jun 13;55(25):7091-7094 [27140428.001]
  • [Cites] Mol Ther. 2009 Jan;17(1):162-8 [18827803.001]
  • [Cites] Nature. 1996 Mar 28;380(6572):364-6 [8598934.001]
  • [Cites] Nat Nanotechnol. 2012 Jun 03;7(6):389-93 [22659608.001]
  • [Cites] Otol Neurotol. 2009 Aug;30(5):661-7 [19546833.001]
  • [Cites] Otol Neurotol. 2012 Dec;33(9):1604-10 [22996162.001]
  • [Cites] Nat Genet. 2016 Nov;48(11):1339-1348 [27723760.001]
  • [Cites] J Cell Biol. 2010 Mar 22;188(6):759-68 [20231381.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):233-47 [16612574.001]
  • [Cites] Otol Neurotol. 2016 Aug;37(7):e203-8 [27295443.001]
  • [Cites] ACS Nano. 2012 Oct 23;6(10):8620-31 [22909216.001]
  • [Cites] Nat Rev Cancer. 2010 Jan;10(1):9-22 [20029421.001]
  • [Cites] Nat Commun. 2016 Jun 28;7:11980 [27351915.001]
  • [Cites] N Engl J Med. 2009 Jul 23;361(4):358-67 [19587327.001]
  • [Cites] Neuro Oncol. 2016 Nov;18(11):1498-1507 [27194145.001]
  • [Cites] Nature. 2007 Jul 5;448(7149):39-43 [17572664.001]
  • [Cites] Hear Res. 2014 Sep;315:25-33 [24910344.001]
  • [Cites] J Assoc Res Otolaryngol. 2013 Dec;14(6):801-11 [23996384.001]
  • [Cites] Nat Mater. 2010 Nov;9(11):923-8 [20935658.001]
  • [Cites] Otol Neurotol. 2012 Aug;33(6):1046-52 [22805104.001]
  • [Cites] Mol Ther. 2006 Sep;14(3):343-50 [16765648.001]
  • [Cites] Sci Transl Med. 2012 Aug 15;4(147):147ra112 [22896676.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1314-8 [15818667.001]
  • [Cites] Front Oncol. 2013 Aug 27;3:216 [23986882.001]
  • [Cites] J Med Chem. 2006 Oct 5;49(20):6087-93 [17004722.001]
  • (PMID = 29018206.001).
  • [ISSN] 2045-2322
  • [Journal-full-title] Scientific reports
  • [ISO-abbreviation] Sci Rep
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA014051; United States / NIDCD NIH HHS / DC / R01 DC015824; United States / NIDCD NIH HHS / DC / T32 DC000038
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Sahin S, Atabey C, Simşek M, Naderi S: Spinal textiloma (gossypiboma): a report of three cases misdiagnosed as tumour. Balkan Med J; 2013 Dec;30(4):422-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal textiloma (gossypiboma): a report of three cases misdiagnosed as tumour.
  • METHODS: This study is a retrospective case series of three patients with retained surgical textile products who had been misdiagnosed with spinal tumour.
  • All three cases had been misdiagnosed as a spinal tumor based on magnetic resonance imaging findings.
  • Neuroradiological findings are variable and non-specific; thus, patients could be misdiagnosed with a spinal tumor or abscess.
  • Likewise, in patients with a history of spinal surgery, spinal abscesses, haematomas, hypertrophic scars, fibrosarcomas, rhabdomyosarcomas, and schwannomas should definitely be considered in the differential diagnosis and considered when planning diagnostic procedures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25207152.001).
  • [ISSN] 2146-3123
  • [Journal-full-title] Balkan medical journal
  • [ISO-abbreviation] Balkan Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC4115950
  • [Keywords] NOTNLM ; Gauze bandage / foreign body granuloma / gossypiboma / lumbar spine / spinal tumour / surgical textile products
  •  go-up   go-down






Advertisement